Mechanisms of mineralocorticoid action

Hypertension

Volumn 46, Issue 6, 2005, Pages 1227-1235

  Fuller, Peter J ^a   Young, Morag J ^a  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Aldosterone; Fibrosis; Sodium channels

Indexed keywords

ALDOSTERONE; EPLERENONE; MINERALOCORTICOID; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; PHOSPHOTRANSFERASE; SODIUM CHANNEL; SPIRONOLACTONE; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE NEDD4-2; UNCLASSIFIED DRUG;

CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; CRYSTAL STRUCTURE; EPITHELIUM; GENETIC REGULATION; HEART FAILURE; HEART MUSCLE FIBROSIS; HORMONAL REGULATION; HORMONE ACTION; HUMAN; HYPERKALEMIA; INFLAMMATION; LIGAND BINDING; MEMBRANE BINDING; MEMBRANE CHANNEL; NEPHROTOXICITY; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RECEPTOR BLOCKING; RECEPTOR INTRINSIC ACTIVITY; REGULATORY MECHANISM; SHORT SURVEY; SODIUM TRANSPORT; TRANSCRIPTION REGULATION;

ALDOSTERONE; ANIMALS; BIOLOGICAL TRANSPORT; CARDIOVASCULAR DISEASES; HUMANS; RECEPTORS, MINERALOCORTICOID; SIGNAL TRANSDUCTION; SODIUM; SODIUM CHANNELS;

EID: 31944432423     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000193502.77417.17     Document Type: Short Survey

References (97)

1. Simpson SA, Tait JF, Wettstein A, Neher R, von Euw J, Reichstein T. Isolierung eines neuen kristallisierten Hormons aus Neben nieren mit besonders hoher Wirksamkeit auf den Mineral-stoffwechsel. Experientia. 1953;9:333-335.
2. Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell. 2001;104:545-556.
3. Kühnle U, Lewicka S, Fuller PJ. Endocrine disorders of sodium regulation. Hormone Res. 2004;61:68-83.
4. Selye H. The general adaptation syndrome and the diseases of adaptation. Practitioner. 1949;163:393-405.
5. Pitt B. Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies. Mol Cell Endocrinol. 2004;217:53-58.
6. Fagart J, Huyet J, Pinon GM, Rochel M, Mayer C, Rafestin-Oblin M-E. Crystal structure of a mutant mineralocorticoid receptor responsible for hypertension. Nat Struct Mol Biol. 2005;12:554-555.
7. Bledsoe RK, Madauss KP, Holt JA, Apolito CJ, Lambert MH. Pearce KH, Stanley TB, Stewart EL, Tramp RP, Willson TM, Williams SP. A ligand-mediated hydrogen bond network required for the activation of the mineralocorticoid receptor. J Biol Chem. 2005;280:31283-31293.
8. Li Y, Suino K, Daugherty J, Xi HE. Structural and biochemical mechanisms for the specificity of hormone binding and coactivator assembly by mineralocorticoid receptor. Mol Cell. 2005;19:367-380.
9. Berger S, Bleich M, Schmid W, Cole TJ, Peters J, Watanabe H, Kriz W, Warth R, Greger R, Schutz G. Mineralocorticoid receptor knockout mice: pathophysiology of Na+ metabolism. Proc Natl Acad Sci U S A. 1998;95:9424-9429.
10. Odermatt A, Arnold P, Frey FJ. The intracellular localization of the mineralocorticoid receptor is regulated by 11beta-hydroxysteroid dehydrogenase type 2. J Biol Chem. 2001;276:28484-28492.
11. Rogerson FM, Fuller PJ. Mineralocorticoid action. Steroids. 2000;65:61-73.
12. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE, Evans RM. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science. 1987;237:268-275.
13. Geller DS, Farhi A, Pinkerton N, Fradley M, Moritz M, Spitzer A, Meinke G, Tsai FTF, Sigler PB, Lifton RP. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science. 2000;289:119-123.
14. Rafestin-Oblin ME, Souque A, Bocchi B. Pinon G, Fagart J, Vandewalle A. The severe form of hypertension caused by the activating S810L mutation in the mineralocorticoid receptor is cortisone related. Endocrinology. 2003;144:528-533.
15. Fuller PJ, Smith BJ, Rogerson FM. Cortisol resistance in the New World revisited. Trends Endocrinol Metab. 2004;15:296-299.
16. Nettles KW, Sun J, Radek JT, Sheng S, Rodriguez AL, Katzenellenbogen JA, Katzenellenbogen BS, Greene GL. Allosteric control of ligand selectivity between estrogen receptors α and β: implications for other nuclear receptors. Mol Cell. 2004;13:317-327.
17. Rogerson FM, Yao Y-Z, Smith BJ, Dimopoulos N, Fuller PJ. Determinants of spironolactone binding specificity in the mineralocorticoid receptor. J Mol Endocrinol. 2003;31:573-582.
18. Rogerson FM, Yao Y, Smith BJ, Fuller PJ. Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor. Clin Exp Physiol Pharmacol. 2004;31:704-710.
19. Pascual-Le Tallec L, Lombès M. The mineralocorticoid receptor: a journey exploring its diversity and specificity of action. Mol Endocrinol. 2005;19:2211-2221.
20. Rogerson FM, Dimopoulos N, Fuller PJ. Interdomain interactions in the mineralocorticoid receptor. Mol Cell Endocrinol. 2003;200:45-55.
21. Glass CK, Rosenfeld MG. Review: The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 2000;14:121-141.
22. Obradovic D, Tirard M, Nemethy Z, Hirsch O, Gronemeyer H, Almeida OF. DAXX, FLASH, and FAF-1 modulate mineralocorticoid and glucocorticoid receptor-mediated transcription in hippocampal cells-toward a basis for the opposite actions elicited by two nuclear receptors? Mol Pharmacol. 2004;65:761-769.
23. Pascual-Le Tallec L, Simone F, Viengchareun S, Meduri G, Thirman MJ, Lombès M. The elongation factor ELL (eleven-nineteen lysine-rich leukemia) is a selective coregulator for steroid receptor functions. Mol Endocrinol. 2005;19:1158-1169.
24. Kitagawa H, Yanigasawa J, Fuse H, Ogawa S, Yogiashi Y, Okuno A, Nagasawa H, Nakajima T, Matsumoto T, Kato S. Ligand-selective potentiation of rat mineralocorticoid receptor activation function 1 by a CBP-containing histone acetyltransferase complex. Mol Cell Biol. 2002;22:3698-3706.
25. Hultman ML, Krasnoperova NV, Li S, Du S, Xia C, Dietz JD, Lala DS, Welsch DJ, Hu X. The ligand-dependent interactin of mineralocorticoid receptor with coactivator and corepressor peptides suggests multiple activation mechanisms. Mol Endocrinol. 2005;19:1460-1473.
26. De Bosscher K, Vanden Berghe W, Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-κB or activator protein-1: molecular mechanisms for gene repression. Endocr Rev. 2003;24:488-522.
27. Kolla V, Litwack G. Inhibition of mineralocorticoid-mediated transcription by NF-kappaB. Arch Biochem Biophys. 2000;383:38-45.
28. McCormick JA, Bhalla V, Pao AC, Pearce D. SGK1: a rapid aldosterone-induced regulator of renal sodium reabsorption. Physiology. 2004;20:134-139.
29. Vallon V, Wulff P, Huang DY, Loffing J, Völkl H, Kuhl D, Lang F. Role of sgk 1 in salt and potassium homeostasis. Am J Physiol. 2005;288:R4-R10.
30. +. J Am Soc Nephrol. 2003;14:1107-1115.
31. Rogerson FM, Brennan FE, Fuller PJ. Dissecting mineralocorticoid receptor structure and function. J Steroid Biochem Mol Biol. 2003;85:389-396.
32. Brennan FE, Fuller PJ. Rapid upregulation of serum and glucocorticoid-regulated kinase (sgk) gene expression by corticosteroids in vivo. Mol Cell Endocrinol. 2000;166:129-136.
33. Bhargava A, Fullerton MJ, Myles K, Purdy TM, Funder JW, Pearce D, Cole TJ. The serum- and glucocorticoid-induced kinase is a physiological mediator of aldosterone action. Endocrinology. 2001;142:1587-1594.
34. Diakov A, Korbmacher C. A novel pathway of epithelial sodium channel activation involves a serum- and glucocorticoid-inducible kinase consensus motif in the C terminus of the channel's α-subunit. J Biol Chem. 2004;279:38134-38142.
35. Boyd C, Naray-Fejes-Toth A. Gene regulation of ENaC subunits by serum and glucocorticoid inducible kinase-1 (SGK1). Am J Physiol. 2005;288:F505-F512.
36. Yoo D, Kim BY, Campo C, Nance L, King A, Maouyo D, Welling PA. Cell surface expression of the ROMK (Kir 1.1) channel is regulated by the aldosterone-induced kinase, SGK-1, and protein kinase A. J Biol Chem. 2003;278:23066-23075.
37. Wulff P, Vallon V, Huang DY, Völkl H, Yu F, Richter K, Jansen M, Schlünz M, Klingel K, Loffing J, Kauselmann G, Bösl M, Lang F, Kuhl D. Impaired renal Na+ retention in the sgk1-knockout mouse. J Clin Invest. 2002;110:1263-1268.
38. Flores SY, Loffing-Cueni D, Kamynina E, Daidie D, Gerbex C, Chabanel S, Dudler J, Loffing J, Staub O. Aldosterone-induced serum and glucocorticoid- induced kinase 1 expression is accompanied by Nedd4-2 phosphorylation and increased Na+ transport in cortical collecting duct cells. J Am Soc Nephrol. 2005;16:2279-2287.
39. Stockand JD. New ideas about aldosterone signaling in epithelia. Am J Physiol. 2002;282:F559-F576.
40. Rogerson FM, Brennan FE, Fuller PJ. Mineralocorticoid receptor binding, structure and function. Mol Cell Endocrinol. 2004;217:203-212.
41. Goldschimdt I, Grahammer F, Warth R, Schulz-Baldes A, Garty H, Greger R, Bleich M. Kidney and colon electrolyte transport in CHIF knockout mice. Cell Physiol Biochem. 2004;14:113-120.
42. Beguin P, Crambert G, Guennoun S, Garty H, Horisberger JD, Geering K. CHIF, a member of the FXYD protein family, is a regulator of Na,K-ATPase distinct from the gamma-subunit. EMBO J. 2001;20:3993-4002.
43. Robert-Nicoud M, Flahaut M, Elalouf JM, Nicod M, Salinas M, Bens M, Doucet A, Wincker P, Artiguenave F, Horisberger JD, Vandewalle A, Rossier BC, Firsov D. Transcriptome of a mouse kidney cortical collecting duct cell line: effects of aldosterone and vasopressin. Proc Natl Acad Sci U S A. 2001;27:2712-2716.
44. Boulkroun S, Fay M, Zennaro M-C, Escoubet B, Jaisser F, Blot-Chabaud M, Farman N, Courtois-Coutry N. Characterization of rat NDRG2 (N-Myc downstream regulated gene 2), a novel early mineralocorticoid-specific induced gene. J Biol Chem. 2002;277:31506-31515.
45. Kellner M, Peiter A, Hafner M, Feuring M, Christ M, Wehling M, Falkenstein E, Lösel R. Early aldosterone upregulated genes: new pathways for renal disease? Kidney Int. 2003;64:1199-1207.
46. Gumz ML, Popp MP, Wingo CS, Cain BD. Early transcriptional effects of aldosterone in a mouse inner medullary collecting duct cell line. Am J Physiol. 2003;285:664-673.
47. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. New Eng J Med. 2004;351:543-551.
48. Wehling M, Kasmayr J, Theisen K. Rapid effects of mineralocorticoids on sodium-proton exchanger: genomic or nongenomic pathway? Am J Physiol. 1991;260:E719-E726.
49. Funder JW. The nongenomic actions of aldosterone. Endocr Rev. 2005;26:313-321.
50. Zhu Y, Bond J, Thomas P. Identification, classification and partial characterization of genes in humans and other vertebrates homologous to a fish membrane progestin receptor. Proc Natl Acad Sci U S A. 2002;100:2237-2242.
51. Revanker CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science. 2005;307:1625-1630.
52. Thomas P, Pang Y, Flardo EJ, Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology. 2005;146:624-632.
53. Zhu W, Smart EJ. Caveolae, estrogen and nitric oxide. Trends Endocrinol Metab. 2003;14:114-117.
54. Alzamora R, Michea L, Marusic ET. Role of 11beta-hydroxysteroid dehydrogenase in nongenomic aldosterone effects in human arteries. Hypertension. 2000;35:1099-1104.
55. Gekle M, Freudinger R, Mildenberger S, Silbernagl S. Rapid actions of aldosterone on cells from renal epithelium: the possible role of EGF-receptor signaling. Steroids. 2002;67:499-504.
56. Haseroth K, Gerdes D, Berger S, Feuring M, Gunther A, Herbst C, Christ M, Wehling M. Rapid nongenomic effects of aldosterone in mineralocorticoid- receptor-knockout mice. Biochem Biophys Res Commun. 1999;266:257-261.
57. Grossmann C, Freudinger R, Mildenberger S, Krug AW, Gekle M. Evidence for epidermal growth factor receptor as negative-feedback control in aldosterone-induced Na+ reabsorption. Am J Physiol. 2004;286:F1226-F1231.
58. Uhrenholdt TR, Schjerning J, Rasmussen LE, Hansen PB. Review. Rapid non-genomic effects of aldosterone on rodent vascular function. Acta Physiol Scand. 2004;181:415-419.
59. Mihailidou AS, Mardini M, Funder JW. Rapid, nongenomic effects of aldosterone in the heart mediated by epsilon protein kinase C. Endocrinology. 2004;145:773-780.
60. Wehling M, Spes CH, Win N, Janson CP, Schmidt BMW, Theisen K, Christ M. Rapid cardiovascular action of aldosterone in man. J Clin Endocrinol Metab. 1998;83:3517-3522.
61. Rad AK, Balment RJ, Ashton N. Rapid natriuretic action of aldosterone in the rat. J Appl Physiol. 2005;98:423-428.
62. Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med. 1992;120:893-901.
63. Young M, Fullerton M, Dilley R, Funder J. Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest. 1994;93:2578-2583.
64. Gomez-Sanchez EP, Venkataraman MT, Thwaites D, Fort C. ICV infusion of corticosterone antagonizes ICV-aldosterone hypertension. Am J Physiol. 1990;258:E649-E653.
65. Qin W, Rudolph AE, Bond BR, Rocha R, Blomme EA, Goellner JJ, Funder JW, McMahon EG. Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ Res. 2003;93:69-76.
66. Young M, Head G, Funder J. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol. 1995;269:E657-E662.
67. Young MJ, Moussa L, Dilley R, Funder JW. Early inflammatory responses in experimental cardiac hypertrophy and fibrosis: effects of 11 beta-hydroxysteroid dehydrogenase inactivation. Endocrinology. 2003;144:1121-1125.
68. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EA, McMahon EG, Delyani JA. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol. 2002;283:H1802-H1810.
69. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol. 2002;161:1773-1781.
70. Barbato JC, Rashid S, Mulrow PJ, Shapiro JI, Franco-Saenz R. Mechanisms for aldosterone and spironolactone-induced positive inotropic actions in the rat heart. Hypertension. 2004;44:751-757.
71. Okoshi MP, Yan X, Okoshi K, Nakayama M, Schuldt AJ, O'Connell TD, Simpson PC, Lorell BH. Aldosterone directly stimulates cardiac myocyte hypertrophy. J Card Fail. 2004;10:511-518.
72. Sato A, Funder JW. High glucose stimulates aldosterone-induced hypertrophy via type I mineralocorticoid receptors in neonatal rat cardiomyocytes. Endocrinology. 1996;137:4145-4153.
73. Ouvrard-Pascaud A, Sainte-Marie Y, Benitah JP, Perrier R, Soukaseum C, Cat AN, Royer A, Le Quang K, Charpentier F, Demolombe S, Mechta-Grigoriou F, Beggah AT, Maison-Blanche P, Oblin ME, Delcayre C, Fishman GI, Farman N, Escoubet B, Jaisser F. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation. 2005;111:3025-3033.
74. Lalevee N, Rebsamen MC, Barrere-Lemaire S, Perrier E, Nargeot J, Benitah JP, Rossier MF. Aldosterone increases T-type calcium channel expression and in vitro beating frequency in neonatal rat cardiomyocytes. Cardiovasc Res. 2005;67:216-224.
75. Tsybouleva N, Zhang L, Chen S, Patel R, Lutucuta S, Nemoto S, DeFreitas G, Entman M, Carabello BA, Roberts R, Marian AJ. Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation. 2004;109:1284-1291.
76. Lee YS, Kim JA, Kim KL, Jang HS, Kim JM, Lee JY, Shin IS, Lee JS, Suh W, Choi JH, Jeon ES, Byun J, Kim DK. Aldosterone upregulates connective tissue growth factor gene expression via p38 MAPK pathway and mineralocorticoid receptor in ventricular myocytes. J Korean Med Sci. 2004;19:805-811.
77. Chun TY, Pratt JH. Aldosterone increases plasminogen activator inhibitor-1 synthesis in rat cardiomyocytes. Mol Cell Endocrinol. 2005;239:55-61.
78. Rude MK, Duhaney TA, Kuster GM, Judge S, Heo J, Colucci WS, Siwik DA, Sam F. Aldosterone stimulates matrix metalloproteinases and reactive oxygen species in adult rat ventricular cardiomyocytes. Hypertension. 2005;46:555-561.
79. Chun TY, Bloem LJ, Pratt JH. Aldosterone inhibits inducible nitric oxide synthase in neonatal rat cardiomyocytes. Endocrinology. 2003;144:1712-1717.
80. Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol. 1994;26:809-820.
81. Fullerton MJ, Funder JW. Aldosterone and cardiac fibrosis: in vitro studies. Cardiovasc Res. 1994;28:1863-1867.
82. Chun TY, Pratt JH. Non-genomic effects of aldosterone: new actions and questions. Trends Endocrinol Metab. 2004;15:353-354.
83. Nagai Y, Miyata K, Sun GP, Rahman M, Kimura S, Miyatake A, Kiyomoto H, Kohno M, Abe Y, Yoshizumi M, Nishiyama A. Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1/2 in rat renal fibroblasts. Hypertension. 2005;46:1039-1045.
84. Robert V, Silvestre JS, Charlemagne D, Sabri A, Trouve P, Wassef M, Swynghedauw B, Delcayre C. Biological determinants of aldosterone-induced cardiac fibrosis in rats. Hypertension. 1995;26:971-978.
85. Beggah AT, Escoubet B, Puttini S, Cailmail S, Delage V, Ouvrard-Pascaud A, Bocchi B, Peuchmaur M, Delcayre C, Farman N, Jaisser F. Reversible cardiac fibrosis and heart failure induced by conditional expression of an antisense mRNA of the mineralocorticoid receptor in cardiomyocytes. Proc Natl Acad Sci U S A. 2002;99:7160-7165.
86. Huang WY, Aramburu J, Douglas PS, Izumo S. Transgenic expression of green fluorescence protein can cause dilated cardiomyopathy. Nat Med. 2000;6:482-483.
87. Christy C, Hadoke PW, Paterson JM, Mullins JJ, Seckl JR, Walker BR. 11beta-hydroxysteroid dehydrogenase type 2 in mouse aorta: localization and influence on response to glucocorticoids. Hypertension. 2003;42:580-587.
88. Robert V, Heymes C, Silvestre JS, Sabri A, Swynghedauw B, Delcayre C. Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. Hypertension. 1999;33:981-986.
89. Provencher PH, Saltis J, Funder JW. Glucocorticoids but not mineralocorticoids modulate endothelin-1 and angiotensin II binding in SHR vascular smooth muscle cells. J Steroid Biochem Mol Biol. 1995;52:219-225.
90. Callera GE, Touyz RM, Teixeira SA, Muscara MN, Carvalho MH, Fortes ZB, Nigro D, Schiffrin EL, Tostes RC. ETA receptor blockade decreases vascular superoxide generation in DOCA-salt hypertension. Hypertension. 2003;42:811-817.
91. Ruiz-Meana M, Garcia-Dorado D, Pina P, Inserte J, Agullo L, Soler-Soler J. Cariporide preserves mitochondrial proton gradient and delays ATP depletion in cardiomyocytes during ischemic conditions. Am J Physiol. 2003;285:H999-H1006.
92. Young M, Funder J. Mineralocorticoid action and sodium-hydrogen exchange: studies in experimental cardiac fibrosis. Endocrinology. 2003;144:3848-3351.
93. Ishizawa K, Izawa Y, Ito H, Miki C, Miyata K, Fujita Y, Kanematsu Y, Tsuchiya K, Tamaki T, Nishiyama A, Yoshizumi M. Aldosterone stimulates vascular smooth muscle cell proliferation via big mitogen-activated protein kinase 1 activation. Hypertension 2005;46:1046-1052.
94. Min LJ, Mogi M, Li JM, Iwanami J, Iwai M, Horiuchi M. Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells. Circ Res. 2005;97:434-442.
95. Funder JW. Mineralocorticoid receptors: distribution and activation. Heart Fail Rev. 2005;10:15-22.
96. Young M, Funder JW. Eplerenone, but not steroid withdrawal, reverses cardiac fibrosis in deoxycorticosterone/salt-treated rats. Endocrinology. 2004;145:3153-3157.
97. Ward MR, Kanellakis P, Ramsey D, Funder J, Bobik A. Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation. 2001;104:467-472.